Novavax Expands Partnership with Sanofi on Matrix-M Adjuvant for Pandemic Influenza Vaccine Candidate

Novavax and Sanofi have expanded their collaboration and license agreement on the use of Novavax's Matrix-M adjuvant in Sanofi's pandemic influenza vaccine candidate program. Sanofi will use the adjuvant in early-stage development through Phase 2, and the companies will negotiate license rates and financial terms if Sanofi enters Phase 3 clinical development. Novavax is eligible to receive up to $200 million for the first four products created by Sanofi using Matrix-M, as well as up to $210 million in milestone payments and ongoing royalties for each product thereafter.